Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00967616 · ClinicalTrials.gov registry record · Phase 2
Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy
A Phase 2 study of Colorectal Cancer and Neoplasms, Colorectal, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 18
- Study locations
NCT00967616 is a Phase 2 study of Colorectal Cancer and Neoplasms, Colorectal that has completed, run by Daiichi Sankyo. The registered enrollment target is 100 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 18 study locations across 6 states.
The verdict
NCT00967616, a Phase 2 study of Colorectal Cancer and Neoplasms, Colorectal, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 18
- Study locations
Study Summary
This phase 2, randomized, active-controlled, open-label, parallel group, multicenter study will be conducted at up to 18 study centers in the US, Central America, and South America. Adult subjects with metastatic colorectal cancer (CRC) who failed first-line chemotherapy will participate in the study, which will be conducted on an outpatient basis. It is anticipated that 100 subjects will be enrolled to obtain approximately 90 evaluable subjects.
Conditions Studied
Interventions
- DRUG CS7017
- DRUG irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Study Locations (18)
Other
- Instituto FIDES Oncologia y Especialidades Medicas - Buenos Aires
- CAIPO Centro para la Atencion Integral del Paciente Oncologico - San Miguel de Tucumán
- Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul - PUC-RS - Porto Alegre
- Instituto Nacional de Cancer INCA - Rio de Janeiro
- ICAVC - São Paulo
- Fundacion Arturo Lopez Perez - Santiago
- Instituto Nacional del Cancer - Santiago
- Instituto Oncologico Clinica Renaca - Viña del Mar
- Hospital Nacional Alberto Sabogai Sologuren - Callao
- Hospital Nacional Dos de Mayo - Lima
- Oncosalud SAC - Lima
- Hospital Nacional Dos de Mayo - Lima
California
- Beverly Hills Cancer Center - Beverly Hills
- St. Jude Heritage Medical Group - Fullerton
District of Columbia
- John Marshall - Washington D.C.
Georgia
- Georgia Cancer Specialists - Atlanta
Maryland
- Victor Priego - Bethesda
Ohio
- Gabrail Cancer Center - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00967616
The ClinicalTrials.gov registry entry for NCT00967616 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which CS7017 is the first listed.
NCT00967616 reports 18 study locations spanning 6 distinct geographic areas - top geographies include Other, California, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00967616 about?
NCT00967616 is a clinical study titled "Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy". This phase 2, randomized, active-controlled, open-label, parallel group, multicenter study will be conducted at up to 18 study centers in the US, Central America, and South America. Adult subjects with metastatic colorectal cancer (CRC) who failed first-line chemotherapy will participate in the stud...
What is the current status of trial NCT00967616?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2009-09. Estimated completion is 2013-04.
What conditions does trial NCT00967616 study?
This clinical trial studies the following conditions: Colorectal Cancer, Neoplasms, Colorectal.
What interventions are being tested in trial NCT00967616?
The interventions under investigation include: CS7017 (DRUG), irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI) (DRUG).
Who is sponsoring clinical trial NCT00967616?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00967616 being conducted?
This trial has 18 study locations across California, District of Columbia, Georgia, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.